——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals...
Hence then, the article about 2025 easl congress spotlight cg 0416 preclinical data unveils a groundbreaking dual action therapy targeting obesity and mash was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( 2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH )
Also on site :
- Thursday: What races the AP has not yet called in contests for Senate and governor
- What to Expect From Best Buy's Black Friday and Cyber Monday Sales This Year
- LEGO’s 2026 Holiday Ad Stars Daft Punk, E.T. & ‘KPop Demon Hunters’: Shop the Sets Featured in the Video